How to buy Chromadex stock (CDXC)

Chromadex is a packaged foods business based in the US. Chromadex shares (CDXC) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.49 – a decrease of 10.73% over the previous week. Chromadex employs 106 staff and has a trailing 12-month revenue of around $91.7 million.

Our top picks for where to buy Chromadex stock

Buy Chromadex stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Chromadex stock price (NASDAQ: CDXC)

Use our graph to track the performance of CDXC stocks over time.

Chromadex shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$5.49
52-week range	$1.36 - $7.97
50-day moving average more info button	$5.68
200-day moving average more info button	$3.80
Wall St. target price	$7.96
PE ratio more info button	285
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$0.02

Is it a good time to buy Chromadex stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Chromadex price performance over time

Historical closes compared with the close of $5.49 from 2024-12-20

1 week (2024-12-16)	-10.73%
1 month (2024-11-22)	-26.21%
3 months (2024-09-23)	46.79%
6 months (2024-06-21)	101.10%

1 year (2023-12-22)	278.62%
2 years (2022-12-23)	266.00%
3 years (2021-12-23)	32.93%
5 years (2019-12-23)	27.97%

Is Chromadex stock undervalued or overvalued?

Valuing Chromadex stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Chromadex's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Chromadex's P/E ratio

Chromadex's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 285x. In other words, Chromadex shares trade at around 285x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Chromadex's EBITDA

Chromadex's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.3 million.

The EBITDA is a measure of a Chromadex's overall financial performance and is widely used to measure a its profitability.

Chromadex financials

Revenue TTM	$91.7 million
Operating margin TTM	6.26%
Gross profit TTM	$42.8 million
Return on assets TTM	0.51%
Return on equity TTM	4.82%
Profit margin	1.62%
Book value	$0.45
Market Capitalization more info button	$435.4 million

TTM: trailing 12 months

Chromadex share dividends

We're not expecting Chromadex to pay a dividend over the next 12 months.

Have Chromadex's shares ever split?

Chromadex's shares were split on a 1:3 basis on 12 April 2016 . So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Chromadex shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Chromadex shares which in turn could have impacted Chromadex's share price.

Chromadex share price volatility

Over the last 12 months, Chromadex's shares have ranged in value from as little as $1.36 up to $7.9738. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Chromadex's is 1.88. This would suggest that Chromadex's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Chromadex overview

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN. com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.

Frequently asked questions

null
What percentage of Chromadex is owned by insiders or institutions?
Currently 35.415% of Chromadex shares are held by insiders and 23.918% by institutions. How many people work for Chromadex?
Latest data suggests 106 work at Chromadex. When does the fiscal year end for Chromadex?
Chromadex's fiscal year ends in December. Where is Chromadex based?
Chromadex's address is: 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024 What is Chromadex's ISIN number?
Chromadex's international securities identification number is: US1710774076 What is Chromadex's CUSIP number?
Chromadex's Committee on Uniform Securities Identification Procedures number is: 171077407